DrugPatentWatch Database Preview

FLONASE SENSIMIST ALLERGY RELIEF Drug Profile

« Back to Dashboard

Which patents cover Flonase Sensimist Allergy Relief, and when can generic versions of Flonase Sensimist Allergy Relief launch?

Flonase Sensimist Allergy Relief is a drug marketed by Glaxosmithkline Cons and is included in one NDA. There are eight patents protecting this drug.

This drug has two hundred and eighty-three patent family members in forty-one countries.

The generic ingredient in FLONASE SENSIMIST ALLERGY RELIEF is fluticasone furoate. There are twenty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the fluticasone furoate profile page.

Summary for FLONASE SENSIMIST ALLERGY RELIEF

International Patents:	283
US Patents:	8
Applicants:	1
NDAs:	1
Suppliers / Packagers:	2
Bulk Api Vendors:	16
Patent Applications:	529
Formulation / Manufacturing:	see details
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FLONASE SENSIMIST ALLERGY RELIEF
Prior Art and Litigation Support	Order Prior Art and Litigation support for FLONASE SENSIMIST ALLERGY RELIEF
DailyMed Link:	FLONASE SENSIMIST ALLERGY RELIEF at DailyMed

Pharmacology for FLONASE SENSIMIST ALLERGY RELIEF

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Synonyms for FLONASE SENSIMIST ALLERGY RELIEF

(6|A,11|A,16|A,17|A)-6,9-Difluoro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioic Acid S-(Fluoromethyl) Ester

(6alpha,11alpha,14beta,16alpha,17alpha)-6,9-Difluoro-17-{[(Fluoromethyl)sulfanyl]carbonyl}-11-Hydroxy-16-Methyl-3-Oxoandrosta-1,4-Dien-17-Yl Furan-2-Carboxylate

(6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl-2-furancarboxylate

397864-44-7

6alpha,9-Difluoro-17-(((fluoromethyl)sulfanyl)carbonyl)-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl furan-2-carboxylate

6alpha,9-difluoro-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-11beta-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17alpha-yl 2-furoate

779352-12-4

911210-90-7

Alisade

Allermist

Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-17-((2- furanylcarbonyl)oxy)-11-hydroxy-16-methyl-3-oxo-, S-(fluoromethyl) ester, (6alpha,11beta,16alpha,17alpha)-

Arnuity Ellipta

Avamys

Avamys pound>> Veramyst pound>> Allermist

BCP18136

BDBM50354851

CHEBI:74899

CHEMBL1676

D06315

DB08906

DTXSID60228586

Flonase Sensimist

Fluticasone fuorate

Fluticasone furancarboxylate

Fluticasone furoate

Fluticasone furoate (JAN/USAN/INN)

Fluticasone furoate [USAN:INN]

fluticasonum furoas

FT-0668768

Furamist

furoate de fluticasone

furoato de fluticasona

GSK 685 698

GSK 685698

GW 685698

GW 685698X

GW-685698

GW-685698X

GW6

gw685698

GW685698X

JS86977WNV

SCHEMBL140504

UNII-JS86977WNV

Veramyst

Veramyst (TN)

ZINC3992105

US Patents and Regulatory Information for FLONASE SENSIMIST ALLERGY RELIEF

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline Cons	FLONASE SENSIMIST ALLERGY RELIEF	fluticasone furoate	SPRAY, METERED;NASAL	022051-002	Aug 2, 2016		OTC	Yes	Yes			Y	Y
Glaxosmithkline Cons	FLONASE SENSIMIST ALLERGY RELIEF	fluticasone furoate	SPRAY, METERED;NASAL	022051-002	Aug 2, 2016		OTC	Yes	Yes			Y
Glaxosmithkline Cons	FLONASE SENSIMIST ALLERGY RELIEF	fluticasone furoate	SPRAY, METERED;NASAL	022051-002	Aug 2, 2016		OTC	Yes	Yes			Y
Glaxosmithkline Cons	FLONASE SENSIMIST ALLERGY RELIEF	fluticasone furoate	SPRAY, METERED;NASAL	022051-002	Aug 2, 2016		OTC	Yes	Yes			Y

International Patents for FLONASE SENSIMIST ALLERGY RELIEF

Country	Patent Number	Estimated Expiration
Spain	2376104
Hungary	0303354
Brazil	PI0113042
Hong Kong	1115834

Supplementary Protection Certificates for FLONASE SENSIMIST ALLERGY RELIEF

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1305329	300343	Netherlands		300343, 20210803, EXPIRES: 20230110
2506844	LUC00077	Luxembourg		PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
1305329	91429	Luxembourg		91429, EXPIRES: 20230111
1305329	SPC011/2008	Ireland		SPC011/2008: 20081105, EXPIRES: 20230110